Inactivation of AMPK is a major hallmark of metabolic diseases [25, 41, 50–53], while activating AMPK has been shown to protect against NASH [37–42], obesity [43] and type 2 diabetes [44, 45]. Here, PRKAA1 is linked to metabolic dysfunction-associated steatohepatitis.